echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The biopharmaceutical industry is expected to become a new growth point in Changsha.

    The biopharmaceutical industry is expected to become a new growth point in Changsha.

    • Last Update: 2020-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: Haiyuan International (Star Sands) Medical Device Industrial Park project will start construction in Changsha Economic Zone.
    . People's Network Changsha, September 2nd, Haiyuan International (Singsha) Medical Device Industrial Park project will start construction in Changsha, which is a set of research and development, production, transfer of technology results, business incubation, trade show, industry exchanges and other functions in one of the ecological medical device industrial park.
    , there is no doubt that the "two main one special" industry is a distinctive label in Changsha's open area, construction machinery, automobiles and parts industry has been cultivated into a hundred billion-level industry.
    the emergence of a brand-new medical device industrial park, so that many people concerned about the economic development of the park is very happy - Changsha Economic Development Zone has been the basis of the development of the biopharmaceutical industry.
    View Park biopharmaceutical enterprises, from raw material preparation to cutting-edge research and development, from large-scale production to market sales, Changsha through the open area of the biopharmaceutical industry ecosystem climate gradually developed, perhaps in the near future, biomedicine will become the park's new economic growth pole.
    Seconded areas to win small and medium-sized enterprises show vitality of development" has Xiangya this affect the entire southern medical market resources, medical equipment needs to be imported from outside provinces, Hunan, especially Changsha to develop medical device-based biopharmaceutical industry has a natural advantage.
    ", this is Hunan Pea Medical Products Co. , Ltd. Chairman Bean Zhouhui has issued a sentiment.
    Medical is a company capable of producing and selling more than 30 different categories of medical supplies, test preparations and medical devices, such as laparoscopic matchers, endoscopic grips, etc.
    this year's outbreak, Pea Medical looked for possibilities in the crisis, stopping some of its core sector business and formally stepping foot in the mask industry.
    invested more than 400 million yuan in the new lease to build 5000 square meters of 100,000-level purification workshop and sterilization center, and continuously improve the quality of production, so that products quickly obtained the Chinese Medical and Health Products Import and Export Chamber of Commerce announced the EU CE certification, products by the German authoritative testing agency - Nande TUV testing to meet the highest standards of the European Union medical mask "IIR type" grade.
    has also become one of the few hunan Province with domestic and foreign dual certification of medical protective mask manufacturers, and to Germany, France, the United Kingdom, Italy, Belgium, Portugal, Portugal, Switzerland, Croatia and other EU countries export masks, well received by foreign customers.
    the Deno Group, which is owned by Depp Enterprises A.D., is a specialist developer, producer and seller of factory extracts.
    its main product coverage from plant raw materials to finished products separately.
    , the company produces various types of plant Deno Group related person-in-charge, in order to be able to produce high-quality products, the company uses the world's leading natural extraction equipment, to create a continuous reverse-current extraction process production line, thus meeting the industry standards of the internal.
    quality control system.
    data show that there are more than 70 biopharmaceutical SMEs located in various start-up bases in Changsha, most of which are involved in the medical device industry.
    Wu Xincun, director of Changsha's entrepreneurship service center, said that instead, Changsha's biopharmaceutical industry is booming, the foreign military system, beginning to take shape, gathered a large number of pharmaceutical sales, medical device production, inspection and testing, intelligent medical care, health management, pharmaceutical logistics, bioengineering enterprises, biomedicine, a new industry, new plate, new engine is quietly rising, is expected to become a new economic growth pole in Changsha through the open area.
    " biopharmaceutical industry is closely related to people's livelihood, the development potential of a huge sunrise industry, with less land, investment Wu Xincun said, the park has a number of enterprises in research and development design, patent development, talent introduction, model promotion, platform construction and other aspects of fruitful exploration and innovation.
    , as long as the industrial chain is continuously extended and industrial clusters are expanded, the biopharmaceutical industry will become a new 10 billion accumulation of the park, the possibility of hundreds of billions of growth.
    "cutting-edge technology" gathered in the forefront of medical research If medical devices are the real needs of "work in the contemporary", then advanced research in the field of medicine is a necessary exploration of "good in the autumn".
    People who understand the biopharmaceutical industry will know that to go to the forefront of medical research, in Changsha, even from the "two main one special" start, biomedicine is still a rising industry, but has emerged with high-end technology, involved in the field of medical research in the forefront of cutting-edge "players."
    Hunan Source Cell Biotech Co., Ltd. (hereinafter referred to as "Source Biology"), located in Changsha, is a professional army stem cells, immune cells and other human biological resources storage, cell biotechnology research and development, cell product production preparation, clinical application of cell therapy technology, tissue engineering product development, bio-health information management enterprises.
    stem cell industry belongs to regenerative medicine, the equivalent of repairing tissue systems, which can slow aging and repair tissue systems in a new medicine.
    " source biological chairman Hu Bo introduced, at present, the source biological pool of experts at home and abroad, aiming at biotechnology, and actively implement stem cell therapy medical-grade applications as the main body, cell storage business and stem cell consumption-grade (beauty anti-decay) application business for two wings, research and development, marketing, capital three-wheel drive "one-wing three-wheel drive" development strategy.
    it is understood that the source bio-industrial park will be involved in the field of beauty, the second phase will further expand the first phase of stem cell and regenerative medicine transformation and dating biomass and tissue engineering and other related industries.
    is expected to form a hundred billion-level industrial development within 10 years, which will greatly promote the level of stem cell and regenerative medicine technology in Hunan Province.
    Cylon Pharmaceuticals is a company that firmly grasps the pulse of industry development and focuses on technological innovation and new drug research and development.
    understood that the company has equipped a number of U.S. FDA companies to build facilities advanced modern powder needles, freeze-dried powder needles, small-capacity injections, biochemic raw materials.
    , international pharmaceutical research and development institutions recognized large-scale precision instruments.
    has been built hand drugs, slow release drugs, bio-chemical drugs and other scientific research platform.
    pharmaceutical, chemical synthetic API production line, with a complete modern production and inspection equipment, the average one-time, high standards through GMP certification, and continuously recognized by emerging enterprises.
    of Micro-Intellectual Medical Devices Co., Ltd. (hereinafter referred to as "Micro-Intelligence Medical") has also received wide attention in the academic community.
    it is understood that the company was founded by Caltech and Golden Eye Intelligent Biomedical Co., Ltd. (LLC) and its core members, the father of intelligent retina, the 2015 U.S. Supreme Technology Invention Award winner Mark Homer, the founder of the California Institute of Technology's Department of Medical Engineering, the department's director Dai Yichang and several other top engineers in the world industry.
    micro-intelligence medical related person in charge, the company gradually promote a new generation of intelligent retina industrialization and marketization.
    then conduct clinical trials in China and promote their application for the benefit of mankind, so that blind people can see the light again.
    will build a new generation of intelligent retinal products in China, set up an international ophthalmology clinical research hospital and the International College of Ophthalmology, and form an industrialization model of intelligent retinal product development, production, sales, training of ophthalmologists and academic exchanges in ophthalmology.
    center, the global production and marketing center of new products and the global ophthalmology exchange center, forming a high-level ecological circle of ophthalmology, Changsha, China to become the world's ophthalmology capital.
    the market field to make efforts to complete ecological chain accelerated molding for any industry, the market end is an indispensable part of the industrial chain.
    in Changsha, Hunan Province Pharmaceutical Sales Co., Ltd., China Pharmaceutical Group Changsha Medical Devices Co., Ltd. have landed.
    Hunan Province Pharmaceutical Sales Co., Ltd. was founded in October 1997 by the Hunan Provincial Health Department investment, the company's existing various types of housing construction area of nearly 3,691 square meters, including business, office, logistics support, auxiliary housing, such as about 2228 square meters;
    China Pharmaceutical Group is directly managed by the State Council SASAC, China's largest, most complete industrial chain, comprehensive strength of the pharmaceutical and health industry group, to prevent treatment and diagnostic care and other health-related products distribution, retail, research and development and production of the main industry.
    owns 11 wholly owned or controlled subsidiaries and 6 listed companies.
    Among them, China Pharmaceutical Group Changsha Medical Devices Co., Ltd. is a subsidiary of China Pharmaceutical Group, the company registered capital of 10 million yuan, under the instrument sales department, reagent sales department, engineering maintenance department and other departments, is an agent and operating international advanced large-scale inspection equipment, operating room and medical supplies company.
    National Pharmaceutical Group Changsha Medical Devices Co., Ltd. is also the United States Beckman Coulter test products, the United States Wolfensohn test products, Germany's McCormott operating room products Hunan's only designated general agent, including blood cell meters, biochemical, special proteins, chemical luminescence, blood clotting these products in Hunan Central South University Xiang Yayi Hospital, Xiangya II Hospital, Xiangya San Hospital, Wangwang Hospital, Yandi City Center Hospital, Changde City First People's Hospital, Yiyang City Center Hospital and other units are recognized, and with which to establish a good cooperative relationship for the hospital to provide world-class brand inspection products and good after-sales service.
    , Xiangya International Hospital was officially opened in Changsha.
    the newly built Xiangya International Hospital has a total construction area of more than 14,000 square meters and is equipped with departments of digestive medicine, gynecology, internal medicine, surgery, emergency department and so on, in accordance with the standard settings of Grade II-A hospitals.
    , the hospital is also working with Philips, Murray Medical and other international brands to adopt state-of-the-art medical devices.
    "We are committed to building a high standard of international hospital, to meet the medical needs of experts, industrial workers and residents in Changsha.
    " Xiangya International Hospital President Gan Jianhui said that Changsha through the open area of the rapid development of the industry, foreign experts from all over the world are park, for the specific development of the park to contribute wisdom and strength, in order to provide these foreign talents with professional medical help, Xiangya International Hospital to recruit high-quality medical personnel using English conversational skills, improve the follow-up, the hospital will mainly serve the surrounding industrial workers and residents living in the surrounding areas.
    (Eurasian JiangLian)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.